Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis [Hematologic Malignancy]

Conclusion
Haplo-HCT with PT-Cy provides survival outcomes comparable to MSD-HCT, with a significantly lower risk of chronic GVHD.

Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Authors: Ghosh, Karmali, Rocha, Ahn, DiGilio, Hari, Bachanova, Bacher, Dahi, de Lima, DSouza, Fenske, Ganguly, Kharfan-Dabaja, Prestidge, Savani, Smith, Sureda, Waller, Jaglowski, Herrera, Armand, Salit, Wagner-Johnston, Fuchs, Bolanos-Meade, Hamadani Tags: Lymphoma Hematologic Malignancy Source Type: research